uniQure
Develops one-time AAV gene therapies for serious diseases with unmet needs.
$49.46
After-hours close+0.76 (+1.55%)
At close$48.71(−1.73%)
Something off on this page? Send us feedback.
Breakdown13F · Form 4
Institutions 98.28%Insiders 2.00%
Institutions and insiders are filed separately and overlap, so together they can pass the whole company. No split is drawn from them.
Shares outstanding 69.37M · Float 62.23M · 89.7% free float
Institutions13F, as of Jun 30, 2026
301 holders · 68.17M shares · 90 new positions · 180 increased · 62 reduced · 51 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| Avoro Capital Advisors LLC | 6.73M | 9.70% | +768.2K | Aug 14, 2026 |
| JPMorgan Chase & Co | 4.87M | 7.02% | +2.03M | Aug 12, 2026 |
| RTW Investments, LP | 3.94M | 5.68% | +1.36M | Aug 14, 2026 |
| State Street Corp | 2.90M | 4.19% | +643.3K | Aug 7, 2026 |
| Abrdn PLC | 2.85M | 4.11% | −2.46M | Jul 31, 2026 |
| BlackRock, Inc. | 1.88M | 2.71% | +144.0K | Aug 7, 2026 |
| Orbimed Advisors LLC | 1.81M | 2.61% | −328.7K | Aug 14, 2026 |
| Jane Street Group, LLC | 1.61M | 2.32% | +974.5K | Aug 14, 2026 |
Beneficial owners13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| Avoro Capital Advisors LLC | 9.87% | 6.15M | 13G | Feb 17, 2026 ↗ |
| JPMorgan Chase & Co | 7.00% | 4.87M | 13G | Jul 16, 2026 ↗ |
| Aberdeen Group plc | 5.91% | 3.68M | 13G | Jan 29, 2026 ↗ |
| RTW Investments, LP | 5.70% | 3.94M | 13G | Aug 14, 2026 ↗ |
| G1 Execution Services, LLC | 5.70% | 3.54M | 13G | Feb 13, 2026 ↗ |
InsidersForm 4
| Insider | Role | Shares | % outstanding | Filed |
|---|---|---|---|---|
| Matthew C. Kapusta | director, officer: CEO, Managing Director | 519.2K | 0.75% | Jul 7, 2026 |
| Christian Klemt | officer: Chief Financial Officer | 226.6K | 0.33% | Mar 6, 2026 |
| Walid Abi-Saab | officer: Chief Medical Officer | 148.2K | 0.21% | Jul 2, 2026 |
| Jeannette Potts | officer: Chief Legal Officer | 133.2K | 0.19% | Jun 17, 2026 |
| Kylie O'Keefe | officer: Chief Customer & Strat Officer | 108.9K | 0.16% | Jun 12, 2026 |
| Madhavan Balachandran | director | 43.3K | 0.06% | Jun 22, 2026 |
| Jeremy P. Springhorn | director | 43.3K | 0.06% | Jun 12, 2026 |
| David D. Meek | director | 39.7K | 0.06% | Jun 12, 2026 |
| Leonard E. Post | director | 35.5K | 0.05% | Jun 12, 2026 |
| Rachelle Suzanne Jacques | director | 33.9K | 0.05% | Jun 12, 2026 |
1 ten-percent owner holds 4.38M shares by Form 4, outside the officers-and-directors figure above · 12 people have not refiled in the last 18 months (968.0K shares), so they are not in the figure above
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| Jul 2, 2026 | Matthew C. Kapustadirector, officer: CEO, Managing Director | Sale · 3 lots | 21,082 | $45.16 | 519,227 |
| Jun 30, 2026 | Jack Kayedirector | Sale · 2 lots | 21,167 | $46.44 | 25,996 |
| Jun 30, 2026 | Walid Abi-Saabofficer: Chief Medical Officer | Sale · 2 lots | 30,000 | $46.42 | 148,235 |
| Jun 26, 2026 | Walid Abi-Saabofficer: Chief Medical Officer | Sale | 1,434 | $46.86 | 168,235 |
| Jun 25, 2026 | Matthew C. Kapustadirector, officer: CEO, Managing Director | Sale | 28,716 | $50.02 | 519,227 |
| Jun 24, 2026 | Matthew C. Kapustadirector, officer: CEO, Managing Director | Sale | 6,696 | $50.00 | 519,227 |
| Jun 17, 2026 | Jack Kayedirector | Sale | 5,295 | $42.57 | 25,996 |
| Jun 17, 2026 | Madhavan Balachandrandirector | Sale · 3 lots | 11,685 | $45.06 | 43,254 |
| Jun 18, 2026 | Matthew C. Kapustadirector, officer: CEO, Managing Director | Sale · 2 lots | 41,671 | $50.00 | 521,795 |
| Jun 17, 2026 | Matthew C. Kapustadirector, officer: CEO, Managing Director | Sale · 6 lots | 164,429 | $44.32 | 558,810 |
CongressHouse and Senate disclosures
Not reported.